1.
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase...
by Neoptolemos, John P, Prof
The Lancet (British edition), 2017, Vol.389 (10073), p.1011-1024
2.
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial
by Noh, Sung Hoon, Prof
The lancet oncology, 2014, Vol.15 (12), p.1389-1396
3.
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised,...
by Sax, Paul E, Dr Prof
The Lancet (British edition), 2015, Vol.385 (9987), p.2606-2615
4.
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, p...
by Wang-Gillam, Andrea, MD
The Lancet (British edition), 2016, Vol.387 (10018), p.545-557
5.
Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials
by Fang, Wenfeng
The lancet oncology, 2018, Vol.19 (10), p.1338-1350
6.
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
by Simkens, Lieke H J, MD
The Lancet (British edition), 2015, Vol.385 (9980), p.1843-1852
7.
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
by Bachelot, Thomas, Dr
The lancet oncology, 2013, Vol.14 (1), p.64-71
8.
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised control...
by Seddon, Beatrice
The lancet oncology, 2017, Vol.18 (10), p.1397-1410
9.
Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial
by Zhang, Li, Prof
The Lancet (British edition), 2016, Vol.388 (10054), p.1883-1892
10.
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
by Bang, Yung-Jue, Prof
The Lancet (British edition), 2012, Vol.379 (9813), p.315-321
11.
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial
by Molina, Jean-Michel, Dr, Prof
The Lancet (British edition), 2011, Vol.378 (9787), p.238-246
12.
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-esca...
by Iveson, Timothy, Dr
The lancet oncology, 2014, Vol.15 (9), p.1007-1018
13.
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, mult...
by O'Hara, Mark H
The lancet oncology, 2021, Vol.22 (1), p.118-131
14.
Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre,...
by Hu, Xi-Chun, Prof
The lancet oncology, 2015, Vol.16 (4), p.436-446
15.
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study
by Lee, Jeeyun, Prof
The lancet oncology, 2012, Vol.13 (2), p.181-188
16.
Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands
by Jansman, Frank G.A
Clinical therapeutics, 2004, Vol.26 (4), p.579-589
17.
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir i...
by Arribas, Jose R, Dr
The Lancet infectious diseases, 2014, Vol.14 (7), p.581-589
18.
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial
by Mukherjee, Somnath, Dr
The lancet oncology, 2013, Vol.14 (4), p.317-326
19.
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial
by Mai, Hai-Qiang
Nature medicine, 2021, Vol.27 (9), p.1536-1543
20.
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo...
by Gane, Edward J, Dr
The Lancet (British edition), 2010, Vol.376 (9751), p.1467-1475
